Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 4, 2003, Pages 625-631

  Ducottet, Cecile ^a   Griebel, Guy ^b   Belzung, Catherine ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b SANOFI   (France)

Author keywords

Antalarmin; BALB c mice; Chronic mild stress (CMS); Corticotropin releasing factor (CRF); Fluoxetine

Indexed keywords

ANTALARMIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TESTING ALTERNATIVE; ARTICLE; BODY WEIGHT; CHRONIC DISEASE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG EXPOSURE; DRUG SELECTIVITY; EMOTION; LONG TERM CARE; MALE; MENTAL STRESS; MOUSE; MOUSE STRAIN; NONHUMAN; WEIGHT GAIN;

EID: 0038689058     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00051-4     Document Type: Article

References (32)

1. Berton O., Durand M., Aguerre S., Mormede P., Chaouloff F. Behavioral, neuroendocrine and serotonergic consequences of single social defeat and repeated fluoxetine pretreatment in the Lewis rat strain. Neuroscience. 92:1999;327-341.
2. Bornstein S.R., Webster E.L., Torpy D.J., Richman S.J., Mitsiades N., Igel M., Lewis D.B., Rice K.C., Joost H.G., Tsokos M., Chrousos G.P. Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology. 139:1998;1546-1555.
3. 1 receptor mRNA expression. J. Neurosci. 15:1995;6340-6350.
4. Chalmers D.T., Lovenberg T.W., Grigoriadis D.E., Behan D.P., De Souza E.B. Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol. Sci. 17:1996;166-172.
5. D'Aquila P.S., Brain P., Willner P. Effects of chronic mild stress on performance in behavioural tests relevant to anxiety and depression. Physiol. Behav. 56:1994;861-867.
6. Deak T., Nguyen K.T., Ehrlich A.L., Watkins L.R., Spencer R.L., Maier S.F., Licinio J., Wong M.L., Chrousos G.P., Webster E., Gold P.W. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology. 140:1999;79-86.
7. Griebel G., Simiand J., Steiberg R., Jung M., Gully D., Roger P., Geslin M., Scatton B., Maffrand J.P., Soubrie P. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4- methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist: II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther. 301:2002;333-345.
8. Griebel G., Simiand J., Serradeil-Le Gal C., Wagnon J., Pascal M., Scatton B., Maffrand J.P., Soubrie P. Anxiolytic and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. U.S.A. 99:2002;6370-6375.
9. Heisler L.K., Kanarek R.B., Gerstein A. Fluoxetine decreases fat and protein intakes but not carbohydrate intake in male rats. Pharmacol, Biochem. Behav. 58:1997;767-773.
10. Heisler L.K., Kanarek R.B., Homoleski B. Reduction of fat and protein intakes but not carbohydrate intake following acute and chronic fluoxetine in female rats. Pharmacol. Biochem. Behav. 63:1999;377-385.
11. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 33:1999;181-214.
12. Holsboer F., Von Bardeleben U., Gerken A., Stalla G.K., Muller O.A. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N. Engl. J. Med. 311:1984;1127.
13. Kasckow J.W., Baker D., Geracioti T.D. Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides. 22:2001;845-851.
14. Keck M.E., Welt T., Wigger A., Renner U., Engelmann M., Holsboer F., Landgraf R. The anxiolytic effect of the CRH1 receptor antagonist R121919 depends on innate emotionality in rats. Eur. J. Neurosci. 13:2001;373-380.
15. Kopp C., Vogel E., Rettori M.C., Delagrange P., Misslin R. The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice. Behav. Pharmacol. 10:1999;73-83.
16. Mansbach R.S., Brooks E.N., Chen Y.L. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur. J. Pharmacol. 323:1997;21-26.
17. Munoz C., Papp M. Alnespirone (S 20499), an agonist of 5-HT1A receptors, and imipramine have similar activity in a chronic mild stress model of depression. Pharmacol. Biochem. Behav. 63:1999;647-653.
18. O'Brien D., Skelton K.H., Owens M.J.J., Nemeroff C.B. Are CRF receptor antagonists potential antidepressants? Hum. Psychopharmacol. 16:2001;81-87.
19. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S.I., Nakazato A., Kumagai T., Okubo T., Tomisawa K. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J. Pharmacol. Exp. Ther. 289:1999;926-935.
20. Papp M., Vassout A., Gentsch C. The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav. Brain Res. 115:2000;19-23.
21. Sanchez C., Papp M. The selective sigma(2) ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. Behav. Pharmacol. 11:2000;117-124.
22. Siegel S., Castellan N.J. Nonparametric Statistics for the Behavioural Sciences. 1988;McGraw-Hill, New York.
23. Vale W.W., Spiess J., Rivier C., Rivier J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin. Science. 213:1981;1394-1397.
24. Vale W.W., Rivier C., Brown M.R., Spiess J., Koob G., Swanson L., Bilezikjian L., Bloom F., Rivier J. Chemical and biological characterization of corticotropin-releasing factor. Recent Prog. Horm. Res. 39:1983;245-270.
25. Webster E.L., Lewis D.B., Torpy D.J., Zachman E.K., Rice K.C., Chrousos G.P. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology. 137:1996;5747-5750.
26. Willner P. The validity of animal models of depression. Psychopharmacology. 83:1984;1-16.
27. Willner P., Mitchell P.J. Animal models of depression: a diathesis/stress approach. D'haenen H., den Boer J.A., Willner P. Biological Psychiatry. vol. II:2002;703-726 Wiley, Chichester, UK.
28. Willner P., Towell A., Sampson D., Sophokleous S. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology. 93:1987;358-364.
29. Willner P., Muscat R., Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci. Biobehav. Rev. 16:1992;525-534.
30. Yamano M., Yuki H., Yasuda S., Miyata K. Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice. J. Pharmacol. Exp. Ther. 292:2000;181-187.
31. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34:2000;171-181.
32. Zorrilla E.P., Valdez G.R., Nozulak J., Koob G.F., Markou A. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res. 952:2002;188-199.